People
After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
San Diego-based Endeavor BioMedicines closed on a Series B financing worth $101 million.
According to Politico, an internal White House investigation confirmed the alleged abuses from Lander, the president and founding director of the Broad Institute.
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
PRESS RELEASES